Roble Belko & Company’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5K | Hold |
25
| – | – | ﹤0.01% | 345 |
|
|
2026
Q1 | $5K | Hold |
25
| – | – | ﹤0.01% | 340 |
|
|
2025
Q4 | $4K | Hold |
25
| – | – | ﹤0.01% | 354 |
|
|
2025
Q3 | $4K | Hold |
25
| – | – | ﹤0.01% | 320 |
|
|
2025
Q2 | $3K | Hold |
25
| – | – | ﹤0.01% | 314 |
|
|
2025
Q1 | $3K | Hold |
25
| – | – | ﹤0.01% | 301 |
|
|
2024
Q4 | $4K | Sell |
25
-25
| -50% | -$4.22K | ﹤0.01% | 279 |
|
|
2024
Q3 | $10K | Hold |
50
| – | – | ﹤0.01% | 231 |
|
|
2024
Q2 | $12K | Hold |
50
| – | – | ﹤0.01% | 230 |
|
|
2024
Q1 | $11K | Hold |
50
| – | – | ﹤0.01% | 239 |
|
|
2023
Q4 | $13K | Hold |
50
| – | – | ﹤0.01% | 225 |
|
|
2023
Q3 | $13K | Hold |
50
| – | – | ﹤0.01% | 203 |
|
|
2023
Q2 | $14K | Hold |
50
| – | – | ﹤0.01% | 205 |
|
|
2023
Q1 | $14K | Hold |
50
| – | – | ﹤0.01% | 212 |
|
|
2022
Q4 | $14K | Hold |
50
| – | – | ﹤0.01% | 232 |
|
|
2022
Q3 | $13K | Hold |
50
| – | – | ﹤0.01% | 225 |
|
|
2022
Q2 | $10K | Hold |
50
| – | – | ﹤0.01% | 241 |
|
|
2022
Q1 | $11K | Hold |
50
| – | – | ﹤0.01% | 280 |
|
|
2021
Q4 | $12K | Hold |
50
| – | – | ﹤0.01% | 255 |
|
|
2021
Q3 | $14K | Hold |
50
| – | – | ﹤0.01% | 229 |
|
|
2021
Q2 | $17K | Hold |
50
| – | – | ﹤0.01% | 232 |
|
|
2021
Q1 | $14K | Hold |
50
| – | – | ﹤0.01% | 234 |
|
|
2020
Q4 | $12K | Hold |
50
| – | – | ﹤0.01% | 229 |
|
|
2020
Q3 | $14K | Hold |
50
| – | – | ﹤0.01% | 210 |
|
|
2020
Q2 | $13K | Hold |
50
| – | – | ﹤0.01% | 233 |
|
|
2020
Q1 | $16K | Hold |
50
| – | – | 0.01% | 206 |
|
|
2019
Q4 | $15K | Hold |
50
| – | – | ﹤0.01% | 238 |
|
|
2019
Q3 | $12K | Hold |
50
| – | – | ﹤0.01% | 245 |
|
|
2019
Q2 | $12K | Sell |
50
-10
| -17% | -$2.31K | ﹤0.01% | 241 |
|
|
2019
Q1 | $14K | Hold |
60
| – | – | ﹤0.01% | 192 |
|
|
2018
Q4 | $18K | Hold |
60
| – | – | 0.01% | 158 |
|
|
2018
Q3 | $21K | Hold |
60
| – | – | 0.01% | 158 |
|
|
2018
Q2 | $17K | Sell |
60
-1,236
| -95% | -$347K | 0.01% | 174 |
|
|
2018
Q1 | $355K | Buy |
1,296
+23
| +2% | +$7.14K | 0.14% | 42 |
|
|
2017
Q4 | $406K | Buy |
1,273
+135
| +12% | +$43.3K | 0.17% | 40 |
|
|
2017
Q3 | $356K | Sell |
1,138
-250
| -18% | -$74K | 0.16% | 38 |
|
|
2017
Q2 | $377K | Hold |
1,388
| – | – | 0.18% | 38 |
|
|
2017
Q1 | $380K | Sell |
1,388
-130
| -9% | -$36.8K | 0.19% | 37 |
|
|
2016
Q4 | $430K | Sell |
1,518
-334
| -18% | -$99K | 0.23% | 35 |
|
|
2016
Q3 | $580K | Buy |
1,852
+29
| +2% | +$8.59K | 0.31% | 34 |
|
|
2016
Q2 | $441K | Buy |
1,823
+90
| +5% | +$23.7K | 0.24% | 36 |
|
|
2016
Q1 | $451K | Buy |
1,733
+17
| +1% | +$4.49K | 0.26% | 35 |
|
|
2015
Q4 | $526K | Hold |
1,716
| – | – | 0.32% | 35 |
|
|
2015
Q3 | $501K | Hold |
1,716
| – | – | 0.31% | 36 |
|
|
2015
Q2 | $693K | Hold |
1,716
| – | – | 0.4% | 35 |
|
|
2015
Q1 | $725K | Buy |
+1,716
| New | +$676K | 0.42% | 35 |
|
Other funds holding BIIB
Roble Belko & Company's BIIB Position: Q2 2026 in Review
Roble Belko & Company held its Biogen (BIIB) position steady in Q2 2026 at 25 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #345.
Roble Belko & Company first reported a position in BIIB in Q1 2015 and has held it in 46 quarters since. The position peaked at $725K in Q1 2015. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Roble Belko & Company held 25 shares of Biogen worth $5K as of Q2 2026.
- Roble Belko & Company left its Biogen share count unchanged in Q2 2026.
- Biogen made up ﹤0.01% of Roble Belko & Company's portfolio in Q2 2026, its #345 holding.
- Roble Belko & Company first reported a position in Biogen in Q1 2015 and has held it in 46 quarters since.
- Roble Belko & Company's Biogen position peaked at $725K in Q1 2015.
- 1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.